A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:3
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [1] Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
    Adeyemi, Ayoade
    Razakariasa, Francesca
    Chiorean, Alexandra
    Sousa, Rui de Passos
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (06)
  • [2] Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura
    Bae, Sung Hwa
    Kim, Sung-Hyun
    Bang, Soo-Mee
    BLOOD RESEARCH, 2022, 57 : 37 - 43
  • [3] Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura
    Truma, Addolorata
    Mancini, Ilaria
    Agosti, Pasquale
    Artoni, Andrea
    Giannotta, Juri Alessandro
    Ferrari, Barbara
    De Leo, Pasqualina
    Peyvandi, Flora
    THROMBOSIS RESEARCH, 2024, 243
  • [4] Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura
    Comparon, Celine
    Galicier, Lionel
    Rebibou, Jean Michel
    Coppo, Paul
    Benhamou, Ygal
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (02) : 157 - 160
  • [5] Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura
    Poullin, P.
    Bornet, C.
    Veyradier, A.
    Coppo, P.
    DRUGS OF TODAY, 2019, 55 (06) : 367 - 376
  • [6] Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Ozpolat, Hasan Tahsin
    Stolla, Moritz
    BLOOD TRANSFUSION, 2023, 21 (05) : 369 - 374
  • [7] Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura
    Weisinger, Julia
    Bouzid, Raida
    Ranta, Dana
    Woaye-Hune, Pascal
    Cohen-Aubart, Fleur
    Gaible, Clotilde
    Marjanovic, Zora
    Corre, Elise
    Joly, Anne-Christine
    Baylatry, Minh-Tam
    Joly, Berangere S.
    Veyradier, Agnes
    Coppo, Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1951 - 1958
  • [8] Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point
    Poullin, P.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (04) : 380 - 385
  • [9] Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults
    Blennerhassett, Richard
    Curnow, Jennifer
    Pasalic, Leonardo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2020, 46 (03) : 289 - 301
  • [10] Efficacy and Safety of Obinutuzumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Weisinger, Julia
    Bouzid, Raida
    Fadlallah, Jehane
    Barbet, Christelle
    Provot, Francois
    Poullin, Pascale
    Neel, Antoine
    Marie, Manon
    Rieu, Virginie
    Kanouni, Tarik
    Moranne, Olivier
    Azoulay, Elie
    Marjanovic, Zora
    Corre, Elise
    Joly, Anne-Christine
    Baylatry, Minh-Tam
    Joly, Berangere S.
    Veyradier, Agnes
    Coppo, Paul
    French Natl Ctr Thrombotic Microangiopathies CNR-MAT
    AMERICAN JOURNAL OF HEMATOLOGY, 2024,